Is Sermorelin Legal in Georgia? How to Access It Legally

What Sermorelin Is and Why Its Legal Classification Matters

Sermorelin is a synthetic 29-amino-acid analogue of endogenous growth hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and stimulates pulsatile secretion of growth hormone (GH), which in turn drives hepatic production of insulin-like growth factor-1 (IGF-1). Because it works upstream of GH itself, it does not directly introduce exogenous GH into the body.

FDA Approval History

Sermorelin acetate was once FDA-approved as Geref (Serono Laboratories) for the diagnosis and treatment of GH deficiency in children. The manufacturer voluntarily withdrew that New Drug Application in 2008 for commercial reasons, not for safety or efficacy concerns. The withdrawal left sermorelin without an active NDA, which is why it now lives entirely within the compounding pharmacy framework rather than the conventional drug-supply chain.

The FDA confirmed in its 2019 guidance on bulk drug substances that sermorelin may be compounded under Section 503A of the Federal Food, Drug, and Cosmetic Act for patient-specific prescriptions [1]. This single regulatory fact is what makes sermorelin accessible to patients in every U.S. State, including Georgia, as long as the dispensing pharmacy and the prescribing clinician follow the applicable rules.

Why "No Active NDA" Does Not Mean Illegal

A common misconception is that a drug without a current FDA approval is therefore illegal. That conflates two separate regulatory categories. Sermorelin is not a controlled substance under the Controlled Substances Act [2]. It carries no DEA schedule. Its legal pathway is simply narrower than that of a fully approved drug: it must be compounded to order for an individual patient by a licensed pharmacy operating under federal and state oversight.

Federal Framework: 503A vs. 503B Compounding

Understanding how sermorelin reaches a Georgia patient requires separating two distinct federal compounding categories established by the Drug Quality and Security Act of 2013.

503A: Traditional Compounding Pharmacies

Section 503A of the FDCA governs traditional compounding pharmacies that prepare medications for identified individual patients based on a valid prescription [3]. Key requirements include:

• The bulk substance must appear on the FDA's 503A Bulks List or otherwise qualify under the statutory criteria.
• The compound must not be a copy of a commercially available drug.
• The prescription must come from a practitioner with a valid patient-prescriber relationship.
• The pharmacy must be licensed in the state where it operates and, for interstate shipments, in the patient's state.

Sermorelin meets the 503A criteria. It has no commercially available equivalent since Geref was withdrawn, and the FDA has not placed it on the "do not compound" list [4].

503B: Outsourcing Facilities

Section 503B outsourcing facilities can produce larger batches without patient-specific prescriptions, but they operate under stricter FDA oversight including Current Good Manufacturing Practice (CGMP) standards [5]. A 503B facility may produce sermorelin for healthcare providers who then administer or dispense it in an office setting. For Georgia patients obtaining sermorelin to self-inject at home, 503A is the more common pathway.

The Bulk Substance Distinction

The FDA periodically reviews which substances may be used in compounding. Sermorelin has not appeared on the agency's Category 1 or Category 2 "do not compound" lists as of the date of this review. Patients and prescribers should confirm current status at the FDA's bulk drug substances page before initiating therapy, because the agency updates these lists without advance notice [6].

Georgia State Law: What the State Adds to Federal Rules

Georgia does not have a state-specific statute that independently legalizes or restricts sermorelin beyond federal law. The governing framework comes from two sources: the Georgia State Board of Pharmacy and the Georgia Composite Medical Board.

Georgia State Board of Pharmacy

The Georgia State Board of Pharmacy licenses and inspects compounding pharmacies operating within Georgia under O.C.G.A. Title 26, Chapter 4. Pharmacies that compound sermorelin in Georgia must hold an active pharmacy permit and comply with USP <797> sterile compounding standards, since sermorelin is prepared as a sterile injectable solution [7]. Out-of-state pharmacies shipping sermorelin to Georgia patients must hold a nonresident pharmacy permit issued by the Georgia Board.

Georgia Composite Medical Board

The Georgia Composite Medical Board governs physician prescribing under O.C.G.A. Title 43. A prescriber may legally write a sermorelin prescription if a legitimate medical purpose exists and a proper patient-prescriber relationship has been established. Georgia's telemedicine statute (HB 307, enacted 2019) allows that relationship to be formed via a synchronous audio-visual encounter, which is why telehealth-based sermorelin prescriptions are legally sound in the state [8].

Prescriber Scope of Practice

Not only MDs and DOs can prescribe sermorelin in Georgia. Nurse practitioners with full prescriptive authority and physician assistants operating under a supervisory agreement may also write the prescription, as long as sermorelin falls within their scope under their respective licensing boards. Patients should verify that their telehealth provider holds an active Georgia license before proceeding.

Clinical Rationale: Who Is a Candidate for Sermorelin?

Legal access is only one piece of the picture. A prescriber must identify a legitimate clinical indication before writing the prescription.

Growth Hormone Deficiency in Adults

Adult GH deficiency (AGHD) is diagnosed when a stimulation test produces a peak GH response below the assay-specific cutoff, typically <3 to <5 ng/mL depending on the protocol used [9]. The Endocrine Society's 2011 clinical practice guideline on AGHD states: "We recommend treating adults with GH deficiency with GH, with goals of normalizing IGF-1 concentrations and improving quality of life, body composition, and metabolic parameters" [10]. Sermorelin, by stimulating endogenous GH release, can raise IGF-1 into the normal range for age and sex in patients with intact pituitary reserve.

Age-Related GH Decline

Pituitary GH secretion declines approximately 14% per decade after age 30, with mean 24-hour GH secretion in adults over 60 roughly 50% lower than in young adults [11]. Sermorelin is sometimes prescribed off-label for this physiological decline when symptomatic. A 2001 study published in the Journal of Clinical Endocrinology and Metabolism found that GHRH analogue therapy in older adults increased mean IGF-1 by 55% over 12 weeks compared to placebo (P<0.001) [12]. Prescribers must weigh off-label use carefully and document the clinical reasoning.

Conditions That Contraindicate Sermorelin

Active malignancy is a hard contraindication, because GH and IGF-1 can stimulate tumor proliferation [13]. Patients with untreated hypothyroidism may have blunted responses, since thyroid hormone is permissive for GH secretion. Pregnancy and breastfeeding are relative contraindications given the absence of safety data.

How to Get Sermorelin in Georgia: Step-by-Step

The process below applies to any Georgia resident seeking sermorelin through a legal, compliant pathway.

Step 1: Establish Care with a Licensed Prescriber

Find a board-certified physician, DO, NP, or PA who holds an active Georgia license and has experience in endocrinology, men's health, women's health, or functional medicine. Telehealth platforms that prescribe sermorelin must comply with Georgia telemedicine rules, which require a synchronous video visit for new patient relationships under most circumstances.

Step 2: Obtain the Required Laboratory Work

A prescriber evaluating a patient for sermorelin should order, at minimum:

• Serum IGF-1 (age- and sex-adjusted reference range)
• IGFBP-3
• Fasting glucose and HbA1c (sermorelin may transiently reduce insulin sensitivity)
• A GH stimulation test if formal AGHD diagnosis is the goal
• Thyroid panel (TSH, free T4) to exclude confounding hypothyroidism

The Endocrine Society guideline specifies that IGF-1 measurement alone is insufficient to diagnose AGHD and that a provocative test is required for a definitive diagnosis in most cases [10].

Step 3: Receive and Fill the Prescription

If the prescriber determines sermorelin is appropriate, they send the prescription to a licensed 503A compounding pharmacy. Patients should confirm:

• The pharmacy holds a current Georgia pharmacy permit or a valid nonresident permit to ship into Georgia.
• The compounding facility meets USP <797> sterile standards [7].
• The product label includes lot number, beyond-use date, and prescriber information.

Reputable pharmacies that compound peptides are accredited by the Pharmacy Compounding Accreditation Board (PCAB), which is a voluntary but meaningful quality signal.

Step 4: Store and Administer Correctly

Compounded sermorelin typically arrives as a lyophilized powder that is reconstituted with bacteriostatic water. Reconstituted solution is stored refrigerated at 2 to 8°C and discarded after 30 days. The standard starting dose is 200 to 500 mcg injected subcutaneously in the abdominal fat pad within 30 minutes before bedtime, timed to coincide with physiological nocturnal GH pulses [14].

Step 5: Monitor and Adjust

Follow-up IGF-1 testing at 8 to 12 weeks is standard practice. The target is an IGF-1 in the upper-normal range for the patient's age and sex, not supraphysiological. Fasting glucose should be rechecked at the same interval because GH excess can impair insulin sensitivity [15].

Sermorelin vs. Other GHRH Peptides: Legal Distinctions That Matter in Georgia

Patients researching sermorelin often encounter related peptides. Their legal statuses differ materially.

CJC-1295

CJC-1295 is a modified GHRH analogue with a longer half-life than sermorelin. The FDA placed CJC-1295 (with and without DAC) on its list of bulk drug substances that may NOT be used in compounding under 503A, effective October 2023 [16]. This means CJC-1295 cannot be legally compounded for patient use in Georgia or any other state under federal law. Any pharmacy offering it should be viewed with serious skepticism.

Ipamorelin

Ipamorelin is a GH secretagogue that works through the ghrelin receptor rather than the GHRH receptor. The FDA's position on ipamorelin for compounding was under active review as of early 2025. Patients should confirm its current status directly with their prescriber and pharmacy.

Tesamorelin

Tesamorelin (Egrifta) holds an active FDA approval for HIV-associated lipodystrophy [17]. Because a commercially available version exists, 503A compounding of tesamorelin for indications other than HIV lipodystrophy occupies a legally ambiguous space. Prescribers should proceed cautiously.

Risks of Obtaining Sermorelin Outside Legal Channels

Some websites sell "research-grade" sermorelin labeled "not for human use." Purchasing this product and self-administering it carries serious risks beyond the obvious safety concerns.

Quality and Sterility

Research-grade peptides are not manufactured under USP <797> or CGMP standards. A 2018 analysis published in JAMA Internal Medicine found that growth hormone products obtained outside licensed pharmacies contained wrong doses, microbial contamination, or no active ingredient in a significant proportion of samples reviewed [18]. The same risk applies to peptides sold in gray markets.

Legal Exposure

Possessing a prescription drug without a valid prescription is a misdemeanor under Georgia law (O.C.G.A. §16-13-78) and may violate federal law depending on the substance and quantity. While enforcement against individual patients for personal-use quantities of non-scheduled peptides is rare, the legal exposure is real.

No Physician Oversight

Without a prescriber monitoring IGF-1 and glucose, a patient has no reliable way to detect early signs of GH excess: carpal tunnel symptoms, fluid retention, joint pain, and impaired glucose regulation [15].

What to Look for in a Georgia Sermorelin Provider

Quality markers vary widely across clinics and telehealth platforms. A compliant provider should:

• Require lab work before prescribing (not after).
• Write the prescription to a named 503A or 503B pharmacy, not dispense pre-made kits directly.
• Monitor IGF-1 at baseline and at 8 to 12 weeks.
• Document a clinical rationale in the medical record.
• Disclose that sermorelin is a compounded, off-label therapy in most adult applications.

Providers who skip lab work, offer automatic refills without follow-up, or ship sermorelin without a pharmacy intermediary are not operating within the legal framework described above.

Cost and Insurance Considerations

Compounded sermorelin is not covered by Medicare or most commercial insurance plans because it lacks an active FDA approval. Out-of-pocket costs in Georgia typically range from $150 to $400 per month depending on dose, pharmacy, and whether the telehealth consultation fee is bundled. Some health savings account (HSA) and flexible spending account (FSA) plans cover compounded prescription medications, but patients should verify with their plan administrator. The IRS defines qualified medical expenses to include prescription drugs, and a compounded sermorelin prescription from a licensed prescriber generally qualifies [19].